Kidney Today Blog

In January 2025, FDA approved an injectable form of semaglutide (GLP1-RA) to treat CKD in people with type 2 diabetes. Here are 6 important things you need to know about GLP1-RAs, CKD and the FDA approval.

Results from a recent clinical trial show promise for semaglutide as a treatment to help slow progression of kidney disease and reduce the risk of death from kidney disease or heart disease for people living with diabetic kidney disease. 

The American Heart Association (AHA) defines and officially declares cardiovascular-kidney-metabolic (CKM) syndrome as a specific health condition, acknowledging the overlap between cardiovascular (heart) disease, kidney disease, type 2 diabetes and obesity.

As part of our 2023 Kidney Action Week, AKF hosted a virtual Congressional briefing called Upstream Solutions to Chronic Kidney Disease: Diabetes and High Blood Pressure Prevention and Management to discuss the growing rate of chronic kidney disease (CKD) in the U.S.

4 things you may not know about the connection between your heart and kidneys

AKF Clinical Scientist in Nephrology Fellow Christine P. Limonte describes some of the advances in understanding and treating diabetic kidney disease in the last 10 years

This May, Janet Faggella Howard braved the Florida summer heat to participate in AKF's 37 Mile Challenge in honor of her son, Bryan, who has been living with kidney disease since 2008.

To celebrate Heart Month, we spoke with AKF's newest Kidney Kidney Kitchen®, NIH NHLBI's The Heart Truth program, and our friends NIDDK about how people with kidney disease can manage their heart health through food. Learn what they had to say on our blog.

Nine years at stage 3 kidney disease and holding—Gail Rae-Garwood shares her experience about slowing down kidney disease.